Cargando…

MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway

Emerging evidence has shown that microRNA-126 (miR-126) is aberrantly downregulated and plays a vital role in carcinogenesis in various cancers, including HCC. However, the underlying biological mechanisms of miR-126 in HCC are still largely unknown. In present study, we found that miR-126 was downr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Jie, Yu, Yan, Chen, Jianan, He, Yuting, Chen, Xiaolong, Ren, Zhigang, Xue, Chen, Liu, Liwen, Hu, Qiuyue, Li, Juan, Cui, Guangying, Sun, Ranran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185973/ https://www.ncbi.nlm.nih.gov/pubmed/30315225 http://dx.doi.org/10.1038/s41419-018-1020-0

Ejemplares similares

Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer
por: Chen, Jianan, et al.
Publicado: (2019)

Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer
por: Xue, Chen, et al.
Publicado: (2018)

Association of genetic variants in ATR-CHEK1 and ATM-CHEK2 pathway genes with risk of colorectal cancer in a Chinese population
por: Wang, Shijia, et al.
Publicado: (2018)

CD44 is overexpressed and correlated with tumor progression in gallbladder cancer
por: He, Yuting, et al.
Publicado: (2018)

Associations of ATR and CHEK1 Single Nucleotide Polymorphisms with Breast Cancer
por: Lin, Wei-Yu, et al.
Publicado: (2013)

Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma
por: Zhang, Yingying, et al.
Publicado: (2020)

The Atr-Chek1 pathway inhibits axon regeneration in response to Piezo-dependent mechanosensation
por: Li, Feng, et al.
Publicado: (2021)

Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients
por: Zhu, Weiwei, et al.
Publicado: (2018)

Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy
por: Liu, Xin, et al.
Publicado: (2020)

Classification molecular subtypes of hepatocellular carcinoma based on PRMT-related genes
por: Liu, Liwen, et al.
Publicado: (2023)

Upregulation of miR‐374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer
por: Zhang, Jun, et al.
Publicado: (2018)

RNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells
por: Ragland, Ryan L., et al.
Publicado: (2013)

MiR‐26b suppresses hepatocellular carcinoma development by negatively regulating ZNRD1 and Wnt/β‐catenin signaling
por: Hu, Xiaobo, et al.
Publicado: (2019)

CLK3 Is A Direct Target Of miR-144 And Contributes To Aggressive Progression In Hepatocellular Carcinoma
por: Li, Hua, et al.
Publicado: (2019)

Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
por: Yoshida, Kosuke, et al.
Publicado: (2022)

miR-126 and miR-126*: New Players in Cancer
por: Meister, Jeannette, et al.
Publicado: (2010)

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer
por: Al Nakouzi, Nader, et al.
Publicado: (2014)

Ubiquitin-proteasome system-based signature to predict the prognosis and drug sensitivity of hepatocellular carcinoma
por: Zhang, Jianxiang, et al.
Publicado: (2023)

N6-methyladenosine-related Genomic Targets are Altered in Breast Cancer Tissue and Associated with Poor Survival
por: Liu, Liwen, et al.
Publicado: (2019)

miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
por: Tan, Wenliang, et al.
Publicado: (2021)

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
por: Ruijs, Marielle WG, et al.
Publicado: (2009)

Low UGP2 Expression Is Associated with Tumour Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma
por: Hu, Qiuyue, et al.
Publicado: (2020)

UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370
por: Yu, Yan, et al.
Publicado: (2020)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Targeting miR-126 in Ph+ acute lymphoblastic leukemia
por: Qiao, Junjing, et al.
Publicado: (2023)

The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A
por: Kong, Ranran, et al.
Publicado: (2016)

MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium
por: Cerutti, Camilla, et al.
Publicado: (2017)

Involvement of miR-126 in autoimmune disorders
por: Casciaro, Marco, et al.
Publicado: (2018)

MiR-126 in intestinal-type sinonasal adenocarcinomas: exosomal transfer of MiR-126 promotes anti-tumour responses
por: Tomasetti, Marco, et al.
Publicado: (2018)

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

MiR-195 suppresses non-small cell lung cancer by targeting CHEK1
por: Liu, Ben, et al.
Publicado: (2015)

Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors
por: Pan, You, et al.
Publicado: (2022)

Glycogen Phosphorylase B Is Regulated by miR101-3p and Promotes Hepatocellular Carcinoma Tumorigenesis
por: Cui, Guangying, et al.
Publicado: (2020)

Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma
por: Ren, Zhigang, et al.
Publicado: (2019)

Mild replication stress causes premature centriole disengagement via a sub-critical Plk1 activity under the control of ATR-Chk1
por: Dwivedi, Devashish, et al.
Publicado: (2023)

AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression
por: Felli, N, et al.
Publicado: (2016)

Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics
por: Gao, Yang, et al.
Publicado: (2021)

Population Screening of CHEK2 Mutations in Poland
por: Cybulski, Cezary, et al.
Publicado: (2006)

CHEK2 mutations in pediatric brain tumors
por: Tlais, Dana, et al.
Publicado: (2023)

MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction
por: Li, Xiaojing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gkpontr4sg5vlt8chudf8u32n8